Tag: CAR T-cell
Novartis announces promising five-year data for leukaemia treatment Kymriah
Novartis has shared long-term, five-year follow-up results from its pivotal clinical phase 2 trial, ELIANA, evaluating Kymriah (tisagenlecleucel), the first-ever approved CAR T-cell therapy, in children and young adult patients with relapsed or refractory (r/r) B-cell acute lymphoblastic leukaemia (ALL). Kymriah is a one-off treatment designed to help patients’ immune…
Researchers Develop Allogeneic CART for Relapsed or Refractory T-ALL Using Base Editing
A group of researchers at Children’s Hospital of Philadelphia (CHOP), in collaboration with Beam Therapeutics, have tested and developed an “off-the-shelf” chimeric antigen receptor T-cell (CART) using base editing, which is designed to allow for precise editing of the CART with less risk of unwanted and unforeseen outcomes that may…
Enabling genome editing research | Scientist Live
As researchers using genome editing tools move from basic research to clinical settings, high-quality ancillary materials and documentation are critical. To help researchers meet stringent quality requirements, Thermo Fisher Scientific introduced the new GMP-manufactured Gibco CTS TrueCut Cas9 Protein. TrueCut Cas9 proteins are manufactured with United States Pharmacopeia standards in…
Diffuse Large B-Cell Lymphoma: Causes, Symptoms, Treatment
Diffuse large B-cell lymphoma (DLBCL) is a cancer of the B cells of the lymphatic system. B cells are responsible for producing antibodies, which are highly specific proteins that fight against bacterial and viral infections. When cancer develops in the B cells, it is called a B-cell lymphoma. B-cell lymphoma…
Polatuzumab Vedotin Plus R-CHP Recommended for EU Approval for Previously Untreated DLBCL
The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion in favor of the approval of polatuzumab vedotin for use in combination with rituximab plus cyclophosphamide, doxorubicin, and prednisone in patients with previously untreated diffuse large B-cell lymphoma. The European Medicines Agency’s Committee for…
Gopal Addresses Differences Between Real-World and Clinical Trial Data for DLBCL
During a Targeted Oncology case-based roundtable event, Ajay K. Gopal, MD, discussed the options for second-line and subsequent treatment of a patient with relapsed/refractory diffuse large B-cell lymphoma who refuses CAR T-cell therapy. Targeted OncologyTM: What are the recommended approaches for relapsed/refractory DLBCL in the second-line and subsequent therapies settings?…
A genome-scale screen for synthetic drivers of T cell proliferation
Abramson, J. S. et al. Transcend NHL 001: immunotherapy with the CD19-directed CAR T-cell product JCAR017 results in high complete response rates in relapsed or refractory B-cell non-Hodgkin lymphoma. Blood 128, 4192–4192 (2016). Google Scholar Shifrut, E. et al. Genome-wide CRISPR screens in primary human T cells reveal key regulators…
Axi-cel CAR-T significantly improves EFS among older patients with non-Hodgkin lymphoma
February 16, 2022 3 min read Source/Disclosures Published by: Source: van Meerten T, et al. Abstract PT02-1. Presented at: European Society for Blood and Marrow Transplantation-European Hematology Association 4th European CAR T-cell Meeting (virtual meeting); Feb. 10-12, 2022. Disclosures: van Meerten reports honoraria from Kite Pharma and…
Anti-CD19 CAR T-Cell Therapy for B-Cell Lymphoma
Researchers reported a favorable efficacy and manageable safety profile in anti-CD19 chimeric antigen receptor (CAR) T-cell therapy for adults with B-cell lymphomas. Their data is presented in Frontiers in Genetics. Researchers, led by Wenyujing Zhou, aimed to determine the benefits and risks of anti-CD19 chimeric antigen receptor (CAR) T-cell therapy…
In Brief This Week: Innovent, Senhwa Biosciences, Oric Pharmaceuticals, Dizal Pharmaceutical
NEW YORK – Innovent this week said that pemigatinib (Pemazyre) was approved in Hong Kong as a treatment for locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement. The approval was based on the Phase II FIGHT-202 study, which showed a 37 percent response rate for cholangiocarcinoma patients treated…
FDA Grants Regenerative Medicine Advanced Therapy, Fast Track Designations to Novel CAR T-Cell Therapy for Relapsed, Refractory B-cell Non-Hodgkin Lymphoma
C-CAR039 showed positive efficacy and safety data in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Officials with the FDA have granted both Regenerative Medicine Advanced Therapy (RMAT) Designation and Fast Track Designation to C-CAR039, a novel autologous bi-specific chimeric antigen receptor (CAR) T-cell therapy, for the treatment of patients…
Brem Looks at Multiple Treatments for Patients With DLBCL
During a Targeted OncologyTM Case-Based Roundtable event, Elizabeth A. Brem, MD, an assistant professor in Division of Hematology/Oncology, Department of Medicine at UC Irvine Health in Los Angeles, CA, moderated a discussion about a 43-year-old woman with diffuse large B-cell lymphoma. Targeted Oncology™: What therapeutic options would you consider at…
Barriers to Loncastuximab Before CAR T-Cell Therapy in DLBCL
DISCUSSION QUESTIONS Do you foresee any barriers to using loncastuximab tesirine (Zynlonta) in diffuse large B-cell lymphoma (DLBCL)? If loncastuximab were covered by insurance, would you use it in the second line for patients who decline transplant? DEVA NATHAN, MD: I have different question. Are you willing to replace R-CHOP [rituximab…
The Future of Targeted Therapies in DLBCL
In an interview with Targeted Oncology, Thomas Habermann, MD discusses the current unmet needs in the DLBCL space, along with the future of targeted therapies. While rituximab (Rituxan), cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is a highly effective therapy for diffuse large B-cell lymphoma (DLBCL). However, major unmet clinical needs still exist for patients with…
Fate Therapeutics Highlights Positive Durability of
6 of 10 Patients Naïve to Treatment with Autologous CAR T-cell Therapy Continue in Ongoing Response at Median Follow-up of 9.1 Months, including 4 Patients with >6 Months Follow-up, at ≥90 Million FT516 Cells per Dose 3 of 8 Patients Previously Treated with Autologous CAR T-cell Therapy Achieve Complete Response…
Real-World Study of Tisagenlecleucel in R/R B-Cell Non-Hodgkin Lymphomas Shows Efficacy, Safety
Real-world data on tisagenlecleucel in patients with relapsed/refractory B-cell lymphoma was consistent with the phase 2 JULIET trial, demonstrating favorable efficacy and safety. Real-world data on the use of tisagenlecleucel (Kymriah) showed greater efficacy and a favorable safety profile, according to updated findings from a study of the Center for…
Tafasitamab and Lenalidomide Combo Yields Higher OS vs Standard Options in Relapsed/Refractory DLBCL
Treatment with tafasitamab (Monjuvi) and lenalidomide (Revlimid) provided an overall survival (OS) benefit vs standard options in a population of patients with autologous stem cell transplant (ASCT)–ineligible relapsed/refractory diffuse large B-cell lymphoma (DLBCL), according to findings from an expanded analysis of RE-MIND2 study (NCT04697160) that was presented at the 2021…
EFS improvement with axi-cel CAR-T a ‘breakthrough’ in second-line treatment of DLBCL
December 11, 2021 3 min read Source/Disclosures Published by: Source: Locke FL, et al. Abstract 2. Presented at: ASH Annual Meeting and Exposition; Dec. 11-14, 2021. Disclosures: Kite Pharma sponsored this study. Leslie reports advisory board, consultant or speakers bureau roles with AbbVie, AstraZeneca, BeiGene, Celgene/Bristol Myers…
Tafasitamab/Lenalidomide Improves OS Over Other Options in Retrospective Relapsed/Refractory DLBCL
The combination of tafasitamab (Monjuvi) and lenalidomide (Revlimid) prolonged median overall survival (OS) compared with other standard options for autologous stem cell transplant (ASCT)-ineligible patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), according to a closely matched expanded analysis of the observational, retrospective RE-MIND2 (NCT04697160) study presented at the…
Choosing a Third-Line Treatment for Refractory DLBCL
DISCUSSION QUESTION What are the key factors that influence your decision making for third-line therapy? PAOLO CAIMI, MD: What are the key factors that influence your decision in choice of regimen for patients who are in the third-line therapy? Any comments about the things that you use when you’re thinking about…
